Multiple RAD301 data releases to be presented at EMIM

ASX ANNOUNCEMENT 6 MARCH 2024 Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 Multiple data releases for 68Ga-Trivehexin (RAD 301) to be presented at European Molecular Imaging Meeting Sydney, Australia – 6 March 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that multiple data sets on its 68Ga-Trivehexin (RAD 301) technology will be presented at the European Molecular Imaging Meeting (EMIM), to be held 12-15 March 2024 in Porto, Portugal. Dr Johannes Notni, Chief Scientific Officer of TRIMT GmbH and a member of Radiopharm’s Scientific Advisory Board, will attend the meeting alongside several colleagues to deliver a series of presentations on 68Ga-Trivehexin (RAD 301), including: - ‘Efficient reduction of renal uptake of αvβ6-integrin targeted at Ga-68 PET imaging agents and Lu-177 therapeutics’ – 13 March - ‘Preliminary results of a Phase 2 study: 68Ga-Trivehexin PET/CT of αvβ6-integrin expression in HNSCC and PDAC and correlation with ITGB6 expression’ – 14 March - ‘Relevance of αvβ6-integrin as a theranostic target: In-depth immuno-histochemistry analysis of membranous ITGB6 expression in various human cancers’ – 15 March Dedicated press releases covering each data releases contents will be shared on the day of their presentation. EMIM attracts more than 1,000 international participants where the latest developments in morphological, functional and molecular imaging are presented, including new strategies for image- guided therapies and theranostics. Radiopharm recently dosed the first participant in a Phase I clinical trial for RAD 301 being conducted at the Montefiore Medical Center, Albert Eistein College of Medicine, NY, USA. The study will assess the safety, radiation dosimetry and imaging characteristics of RAD 301 in patients with advanced Pancreatic Ductal Adenocarcinoma (PDAC). For more information, please visit clinicaltrials.gov (NCT05799274). About 68Ga-Trivehexin (RAD 301) Trivehexin is a peptide-based molecule that targets αvβ6-integrin, a cellular marker for tumour invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas. The αvβ6-integrin receptor is found in high density on most pancreatic carcinoma cells, making it an attractive diagnostic and therapeutic target. About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. ASX ANNOUNCEMENT 6 MARCH 2024 Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and brain. Learn more at Radiopharmtheranostics.com. Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Riccardo Canevari CEO & Managing Director P: +1 862 309 0293 E: [email protected] Matt Wright NWR Communications P: +61 451 896 420 E: [email protected] Follow Radiopharm Theranostics: Website – https://radiopharmtheranostics.com/ Twitter – https://twitter.com/TeamRadiopharm Linked In – https://www.linkedin.com/company/radiopharm- theranostics/ InvestorHub – https://investorhub.radiopharmtheranostics.com/

The release as fetched from its publisher. radiopharmtheranostics.com ↗